Skip to main content
. 2015 Feb 20;6:33. doi: 10.3389/fphar.2015.00033

FIGURE 1.

FIGURE 1

Key components of the systems pharmacology model for anti-VEGF therapy. The model integrates the pharmacokinetics of the drug, antitumor activity, circulating angiogenic biomarkers emanated from host and tumor cells, and therapeutic endpoints based on the drug’s response and compensatory mechanisms within a quantitative framework, to realize a bench to bedside paradigm.